Drug developers look at innovative mechanisms to tackle dry eye syndrome
Pharmaceutical Technology
SEPTEMBER 23, 2022
cyclosporine A) is currently at pre-registration stage with the FDA, following results from late-stage clinical trials that demonstrated CyclASol significantly reduced corneal and conjunctival staining, and improved ocular dryness compared with vehicle. Novaliq’s CyclASol (0.1%
Let's personalize your content